Table 2.
Comparison between primary outcomes and secondary outcomes among the MR (methylprednisolone plus ropivacaine) group and the R (ropivacaine) group in the first 48 hours postoperatively.
| Time/variable | MR group (n = 66) | R group (n = 64) | p value | |
|---|---|---|---|---|
| Primary outcome | ||||
| Cumulative sufentanil dose within 48 h (μg) ± SD | 32.5 ± 20.6 | 50.9 ± 27.2 | <0.001 | |
|
| ||||
| Secondary outcomes | ||||
| Cumulative sufentanil dose (μg) | ||||
| 0–4 h, ± SD | 11.5 ± 7.1 | 15.6 ± 8.2 | 0.003 | |
| 4–8 h, ± SD | 9.8 ± 5.6 | 14.6 ± 7.4 | <0.001 | |
| 8–24 h, median (IQR) | 6.0 (4.0, 10.0) | 10.0 (8.0, 16.0) | <0.001 | |
| 24–48 h, median (IQR) | 4.0 (0, 6.5) | 8.0 (4.0, 12.0) | <0.001 | |
|
| ||||
| NRSM, median (IQR) | ||||
| 2 h | 6.0 (5.0, 8.0) | 7.0 (6.0, 9.0) | 0.116 | |
| 4 h | 6.0 (5.0, 7.0) | 7.0 (6.0, 9.0) | 0.006 | |
| 8 h | 5.0 (4.2, 7.0) | 7.0 (5.0, 8.0) | <0.001 | |
| 24 h | 4.0 (3.0, 5.2) | 5.0 (4.0, 7.0) | 0.005 | |
| 48 h | 3.0 (2.0, 5.0) | 5.0 (3.0, 6.0) | 0.003 | |
| 3 days | 2.0 (1.8, 4.0) | 3.0 (2.2, 5.0) | 0.001 | |
| 1 week | 0 (0, 1) | 1 (0, 2) | 0.024 | |
| 2 weeks | 0 (0, 0) | 0 (0, 0) | 0.034 | |
| 4 weeks | 0 (0, 0) | 0 (0, 0) | 0.983 | |
|
| ||||
| NRSR, median (IQR) | ||||
| 2 h | 3.0 (1.0, 4.0) | 4.0 (2.2, 6.0) | 0.007 | |
| 4 h | 2.5 (1.8, 4.0) | 4.0 (2.0, 5.0) | 0.001 | |
| 8 h | 2.0 (1.0, 3.0) | 3.0 (2.2, 5.0) | <0.001 | |
| 24 h | 1.0 (0, 2.0) | 2.0 (1.0, 3.0) | <0.001 | |
| 48 h | 0.5 (0, 1.0) | 2.0 (1.0, 3.0) | <0.001 | |
| 3 days | 0 (0, 1) | 1.0 (0, 2.0) | <0.001 | |
| 1 week | 0 (0, 0) | 0 (0, 0) | 0.061 | |
| 2 weeks | 0 (0, 0) | 0 (0, 0) | 0.076 | |
| 4 weeks | 0 (0, 0) | 0 (0, 0) | 0.983 | |
|
| ||||
| PSS, median (IQR) | ||||
| 2 h | 4.0 (3.0, 6.0) | 4.0 (2.0, 5.0) | 0.078 | |
| 4 h | 5.0 (4.0, 6.0) | 4.0 (2.2, 5.0) | 0.007 | |
| 8 h | 5.0 (5.0, 7.0) | 5.0 (3.0, 6.0) | 0.001 | |
| 24 h | 7.0 (5.0, 8.0) | 5.0 (4.0, 7.0) | 0.003 | |
| 48 h | 8.0 (6.0, 8.0) | 7.0 (6.0, 8.0) | 0.002 | |
| 3 days | 8.0 (7.0, 9.0) | 8.0 (6.0, 8.0) | 0.001 | |
| 1 week | 10.0 (9.0, 10.0) | 9.0 (9.0, 9.0) | <0.001 | |
| 2 weeks | 10.0 (10.0, 10.0) | 10.0 (10.0, 10.0) | 0.220 | |
| 4 weeks | 10.0 (10.0, 10.0) | 10.0 (10.0, 10.0) | 0.325 | |
|
| ||||
| Number of participants who did not receive oral rescue analgesic after the 48-hour postoperative period | 18 (27.3%) | 20 (31.3%) | 0.618 | |
|
| ||||
| Oral rescue analgesics received after the 48-hour postoperative period (tablets)∗ | 0 (0–3) | 0 (0–3) | 0.715 | |
∗ Note: oxycodone and acetaminophen tablets (Mallinckrodt Inc.), each tab containing 5 mg oxycodone hydrochloride (equivalent to 4.4815 mg) and 325 mg acetaminophen.